Tirzepatide acts as a dual GIP and GLP-1 receptor agonist. These receptors are involved in several metabolic functions, particularly insulin production and blood glucose regulation. After administration, the medication stimulates insulin secretion when blood glucose levels are elevated. It also reduces glucagon secretion, a hormone that increases glucose production in the liver.
Its combined hormonal activity influences different processes involved in type 2 diabetes.
Insulin secretion: Tirzepatide helps the pancreas release more insulin in response to elevated blood glucose levels.
Glucagon regulation: It reduces inappropriate glucagon secretion, helping control glucose production by the liver.
Gastric emptying: It slows the movement of food from the stomach, particularly during initial treatment, which can influence post-meal blood glucose levels.
Appetite regulation: It acts on appetite-related pathways, potentially reducing hunger and food intake.
Weight management: Reduced appetite and food consumption can contribute to weight loss in many individuals.
These effects work together to improve glycemic control. Tirzepatide is generally administered once weekly through a subcutaneous injection. The starting dose is typically low and gradually increased by a healthcare professional to improve tolerability.
Clinical studies have demonstrated that tirzepatide can significantly reduce HbA1c levels, which represent average blood glucose over approximately three months. It can also contribute to weight reduction in people with type 2 diabetes. The extent of these effects varies depending on dosage, individual response, other medications, and lifestyle factors.
Important effects associated with tirzepatide include:
HbA1c reduction: The medication helps lower average blood glucose levels and supports long-term diabetes management.
Fasting blood glucose: It can improve glucose levels measured after an overnight fasting period.
Post-meal glucose: Its effects on insulin and glucagon help regulate blood sugar following food consumption.
Body weight reduction: Many individuals experience weight loss due to changes in appetite and food intake.
Insulin sensitivity: Weight reduction may contribute to improvements in the body's response to insulin.
Cardiometabolic factors: Changes in body weight and glucose regulation may also influence certain cardiovascular risk factors.
Tirzepatide may cause side effects, particularly when treatment begins or the dosage increases. Common side effects include nausea, diarrhea, vomiting, constipation, abdominal discomfort, and reduced appetite. These symptoms may become less noticeable as the body adjusts to treatment.
There are also important precautions associated with its use. Tirzepatide can increase the risk of low blood sugar when combined with insulin or certain other diabetes medications, particularly sulfonylureas. It may also cause dehydration if vomiting or diarrhea is persistent.
People with a history of pancreatitis, gallbladder disease, or severe gastrointestinal conditions should discuss their medical history with a healthcare professional before starting treatment. Tirzepatide is not recommended for individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Medical supervision is important when determining whether this medication is appropriate for an individual's diabetes management needs.